Zosuquidar (LY335979) 3HCl: Potent P-glycoprotein Modulator for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent and selective P-glycoprotein (P-gp) inhibitor that reverses multidrug resistance (MDR) in cancer cells by blocking P-gp–mediated drug efflux [APExBIO]. In vitro, low micromolar concentrations restore sensitivity to chemotherapeutics such as vinblastine and doxorubicin in P-gp overexpressing leukemia and solid tumor cell lines (Sun et al., 2025). In vivo, zosuquidar enhances antitumor efficacy and survival in murine models of MDR cancer without altering systemic pharmacokinetics [APExBIO scenario guide]. Clinical trials in non-Hodgkin's lymphoma and advanced solid tumors show minimal toxicity and effective P-gp inhibition [Clinical perspective]. Zosuquidar's activity, selectivity, and workflow compatibility are well-established for translational and preclinical MDR research.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-dependent efflux transporter expressed in human tissues such as brain, liver, intestine, and tumor cells. Its physiological function includes the extrusion of xenobiotics and endogenous metabolites (Sun et al., 2025). In oncology, P-gp mediates multidrug resistance (MDR) by actively transporting chemotherapeutic agents out of malignant cells, thereby reducing their intracellular concentration and efficacy. Upregulation of P-gp is a major mechanism underlying primary and acquired chemotherapy resistance in cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and solid tumors [Precision Reversal of Cancer MDR]. Reversing P-gp–mediated MDR is a validated strategy to restore drug sensitivity and improve clinical outcomes.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a third-generation, non-competitive, and highly selective inhibitor of P-gp. Its chemical name is (2R)-1-(4-((1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol (CAS 167354-41-8, MW 527.6). Zosuquidar binds to the drug-binding sites of P-gp and inhibits the ATPase activity required for substrate transport [APExBIO]. This competitive blockade prevents the efflux of chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel from cancer cells. The result is increased intracellular drug accumulation and enhanced cytotoxicity in P-gp overexpressing cell lines [Unlocking Reliable P-gp Inhibition].

Evidence & Benchmarks

• Zosuquidar at 0.1–1 μM restores vinblastine sensitivity by >20-fold in P-gp–overexpressing leukemia cell lines (Sun et al., 2025, DOI).
• In murine models of MDR leukemia, zosuquidar plus doxorubicin increases median survival by 30–50% compared to doxorubicin alone, with no significant alteration in doxorubicin plasma pharmacokinetics (APExBIO, product data).
• Phase I/II clinical trials in non-Hodgkin’s lymphoma show that zosuquidar combined with CHOP chemotherapy leads to effective P-gp inhibition and no dose-limiting toxicity (Clinical scenario, article).
• In vitro, zosuquidar does not inhibit other common ABC transporters (e.g., MRP1, BCRP) at effective anti-P-gp concentrations—confirming its selectivity (Sun et al., 2025, DOI).
• Zosuquidar is soluble in DMSO up to 50 mM and should be stored at -20°C. Long-term storage of working solutions is not recommended (APExBIO, product page).

This article extends the scenario-driven guidance in "Unlocking Reliable P-gp Inhibition" by providing a consolidated, evidence-led overview of Zosuquidar's mechanistic and translational benchmarks. For a broader contextual discussion, see "Precision Reversal of Cancer Multidrug Resistance", which details emerging transporter biology and clinical trial integration.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is validated for use in preclinical drug resistance models and translational studies focused on reversing P-gp–mediated MDR. It is especially relevant in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and solid tumor systems where P-gp expression is a primary resistance determinant. Zosuquidar is not indicated for clinical use outside of research or investigational trials.

Common Pitfalls or Misconceptions

• Zosuquidar is selective for P-gp: It does not inhibit MRP1, BCRP, or other ABC transporters at pharmacologically relevant concentrations.
• It does not reverse drug resistance mediated by non–P-gp mechanisms: Resistance due to altered drug targets, increased DNA repair, or microenvironmental factors will not be affected.
• Stability limitations: Zosuquidar solutions are unstable for long-term storage; fresh preparations are required for optimal activity.
• Clinical translation is context-dependent: While in vivo and early clinical results are promising, zosuquidar is not an approved therapeutic for MDR reversal in patients.
• Pharmacokinetics may differ by species and co-administered drugs: Workflow-specific validation is necessary for extrapolation to new systems.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl, supplied by APExBIO (SKU A3956), is formulated as a high-purity hydrochloride salt and is soluble in DMSO. For cell-based assays, stock solutions are typically prepared at 10–50 mM in DMSO and diluted to 0.1–2 μM in culture medium. Storage at -20°C is recommended, and repeated freeze-thaw cycles should be avoided. Zosuquidar is compatible with standard cytotoxicity assays (MTT, CellTiter-Glo) and drug accumulation studies using fluorescent or radiolabeled chemotherapeutics. For in vivo studies, dosing regimens and delivery vehicles must be optimized based on animal model and co-administered agents. Refer to the Zosuquidar (LY335979) 3HCl product page for detailed specifications and handling protocols. For troubleshooting and reproducibility guidance, see "Mastering Multidrug Resistance: Scenario Strategies", which focuses on workflow adaptation for high-sensitivity P-gp inhibition.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl provides a robust, selective, and reproducible tool for the reversal of P-glycoprotein–mediated multidrug resistance in cancer research. Its molecular specificity, validated efficacy in vitro and in vivo, and compatibility with a range of assays make it central to translational MDR studies. As new transporter biology and clinical trial data emerge, Zosuquidar is positioned as a reference compound for benchmarking and workflow optimization. Researchers should consult the APExBIO product specification and recent scenario-driven guides to ensure best practices in MDR assay design and drug resistance signaling analysis.